Upadacitinib in a Refractory Case of Alpha-1 Antitrypsin Deficiency-Related Panniculitis [PDF]
Mohammed Faiz Chaoui +3 more
openalex +1 more source
Novel JAK‐1 inhibitor upadacitinib as a possible treatment for refractory SAPHO syndrome: A case report [PDF]
, 2023 Mingwei Ma +3 more
openalex +1 more source
AB0947 EFFECT OF UPADACITINIB ON REDUCING PAIN IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS AND INADEQUATE RESPONSE TO BIOLOGIC THERAPY [PDF]
, 2023 Xenofon Baraliakos +9 more
openalex +1 more source
Short-Term Use of Upadacitinib in Combination With Biologic Therapy for Inducing Clinical Remission in Patients With Active Inflammatory Bowel Disease [PDF]
Jianyi Yin +7 more
openalex +1 more source
301 Treatment of systemic lupus erythematosus patients with upadacitinib results in the coordinated inhibition of type 1 IFN-related biomarkers: biomarker analysis of the M19–130 (SLEek) phase 2 study [PDF]
Marie‐Claude Gaudreau +5 more
openalex +1 more source
EFFICACY OF UPADACITINIB IN PATIENTS PREVIOUSLY TREATED WITH TOFACITINIB FOR THE MANAGEMENT OF ULCERATIVE COLITIS [PDF]
, 2023 Marlana Radcliffe +5 more
openalex +1 more source
More Time Spent with Clear Skin and No Itch with Upadacitinib versus Dupilumab for Atopic Dermatitis
Dermatology and TherapyIntroduction Atopic dermatitis (AD), with its hallmark symptoms of pruritus and skin lesions, often impairs patients’ quality of life. We assessed time spent with clear/almost clear skin and no/minimal itch during upadacitinib treatment versus placebo or
Andrew Blauvelt +13 more
doaj +1 more source
Upadacitinib and vedolizumab combination therapy for the management of refractory ulcerative colitis and Crohn’s disease [PDF]
Robert Gilmore +5 more
openalex +1 more source
Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial [PDF]
, 2022 Martin Bergman +7 more
openalex +1 more source